DP
IBB icon

Dearborn Partners’s iShares Biotechnology ETF IBB Stock Holding History

Dearborn Partners’s Portfolio IBB Stock Details IBB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$905K Buy
5,362
+1
+0% +$171 0.05% 131
2025
Q4 		$905K Buy
5,361
+278
+5% +$45.2K 0.05% 129
2025
Q3 		$734K Sell
5,083
-300
-6% -$41K 0.03% 148
2025
Q2 		$681K Sell
5,383
-88
-2% -$10.8K 0.03% 153
2025
Q1 		$700K Sell
5,471
-90
-2% -$12.2K 0.03% 138
2024
Q4 		$735K Sell
5,561
-499
-8% -$70.2K 0.03% 136
2024
Q3 		$882K Sell
6,060
-210
-3% -$30.4K 0.04% 124
2024
Q2 		$861K Sell
6,270
-161
-3% -$21.5K 0.04% 125
2024
Q1 		$882K Sell
6,431
-115
-2% -$15.7K 0.04% 124
2023
Q4 		$889K Buy
6,546
+1,326
+25% +$162K 0.03% 122
2023
Q3 		$638K Sell
5,220
-50
-0.9% -$6.36K 0.03% 133
2023
Q2 		$669K Hold
5,270
– – 0.03% 129
2023
Q1 		$681K Sell
5,270
-519
-9% -$67.9K 0.03% 129
2022
Q4 		$760K Buy
5,789
+63
+1% +$8.14K 0.03% 127
2022
Q3 		$670K Sell
5,726
-25
-0.4% -$3.1K 0.03% 133
2022
Q2 		$676K Sell
5,751
-153
-3% -$18.2K 0.03% 136
2022
Q1 		$769K Buy
5,904
+150
+3% +$19.5K 0.03% 138
2021
Q4 		$878K Buy
5,754
+216
+4% +$33.4K 0.03% 125
2021
Q3 		$895K Sell
5,538
-62
-1% -$10.4K 0.04% 120
2021
Q2 		$916K Sell
5,600
-162
-3% -$25K 0.04% 122
2021
Q1 		$867K Buy
5,762
+25
+0.4% +$3.97K 0.04% 115
2020
Q4 		$869K Hold
5,737
– – 0.04% 119
2020
Q3 		$777K Buy
5,737
+1
+0% +$136 0.04% 113
2020
Q2 		$784K Hold
5,736
– – 0.04% 108
2020
Q1 		$618K Buy
5,736
+63
+1% +$7.25K 0.04% 111
2019
Q4 		$684K Sell
5,673
-326
-5% -$36.4K 0.03% 123
2019
Q3 		$597K Sell
5,999
-639
-10% -$66.9K 0.03% 118
2019
Q2 		$724K Buy
6,638
+21
+0.3% +$2.23K 0.04% 105
2019
Q1 		$740K Buy
6,617
+100
+2% +$11K 0.05% 98
2018
Q4 		$628K Buy
6,517
+2,833
+77% +$301K 0.05% 109
2018
Q3 		$449K Buy
+3,684
New +$434K 0.03% 127
2016
Q1 		– Sell
-2,061
Closed -$232K – 197
2015
Q4 		$232K Sell
2,061
-528
-20% -$57.3K 0.02% 204
2015
Q3 		$262K Sell
2,589
-735
-22% -$88.2K 0.03% 191
2015
Q2 		$409K Sell
3,324
-8,400
-72% -$1.01M 0.04% 171
2015
Q1 		$1.34M Sell
11,724
-207
-2% -$22.8K 0.12% 145
2014
Q4 		$1.21M Buy
11,931
+195
+2% +$19K 0.11% 159
2014
Q3 		$1.07M Buy
11,736
+222
+2% +$19.5K 0.1% 162
2014
Q2 		$987K Buy
11,514
+651
+6% +$51.3K 0.1% 168
2014
Q1 		$856K Buy
10,863
+348
+3% +$29K 0.09% 175
2013
Q4 		$796K Buy
10,515
+3,258
+45% +$231K 0.09% 177
2013
Q3 		$507K Buy
7,257
+1,692
+30% +$111K 0.07% 204
2013
Q2 		$323K Buy
+5,565
New +$322K 0.05% 233

Other funds holding IBB

Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
Citigroup
Citigroup New York $235B AUM 32.99% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
BNP Paribas Financial Markets
BNP Paribas Financial Markets Paris, France $206B AUM 31.61% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
Envestnet Asset Management
Envestnet Asset Management Chicago, Illinois $374B AUM 17.66% 1-Year Est. Return
Raymond James Financial
Raymond James Financial St Petersburg, Florida $324B AUM 22.36% 1-Year Est. Return
CB
Commerce Bank Kansas City, Missouri $20.7B AUM 23.76% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return

Dearborn Partners's IBB Position: Q1 2026 in Review

Dearborn Partners increased its iShares Biotechnology ETF (IBB) stake by 0.02% in Q1 2026, buying an estimated $171 and bringing the position to 5,362 shares worth $905K. The position accounts for 0.05% of the portfolio, ranked #131.

Dearborn Partners first reported a position in IBB in Q2 2013 and has held it in 42 quarters since. The position peaked at $1.34M in Q1 2015. 917 funds tracked by Wall St. Rank hold IBB as of Q1 2026.

  • Dearborn Partners held 5,362 shares of iShares Biotechnology ETF worth $905K as of Q1 2026.
  • Dearborn Partners bought 1 iShares Biotechnology ETF share in Q1 2026, an estimated $171.
  • iShares Biotechnology ETF made up 0.05% of Dearborn Partners's portfolio in Q1 2026, its #131 holding.
  • Dearborn Partners first reported a position in iShares Biotechnology ETF in Q2 2013 and has held it in 42 quarters since.
  • Dearborn Partners's iShares Biotechnology ETF position peaked at $1.34M in Q1 2015.
  • 917 funds tracked by Wall St. Rank held iShares Biotechnology ETF as of Q1 2026.

Based on Dearborn Partners's 13F filing for Q1 2026, filed 12 May 2026.